Lantheus Holdings Inc (LNTH) Receives Average Recommendation of “Hold” from Analysts

Lantheus Holdings Inc (NASDAQ:LNTH) has been assigned an average rating of “Hold” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $20.50.

Several equities analysts recently commented on LNTH shares. Credit Suisse Group reduced their target price on Lantheus from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Thursday, August 2nd. BidaskClub upgraded Lantheus from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. ValuEngine cut Lantheus from a “hold” rating to a “sell” rating in a research report on Wednesday, October 31st. Wells Fargo & Co reduced their target price on Lantheus from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, August 2nd. Finally, Zacks Investment Research cut Lantheus from a “hold” rating to a “sell” rating in a research report on Saturday, August 4th.

A number of hedge funds have recently modified their holdings of the business. Globeflex Capital L P lifted its stake in Lantheus by 3.1% during the second quarter. Globeflex Capital L P now owns 126,100 shares of the medical equipment provider’s stock worth $1,835,000 after purchasing an additional 3,800 shares during the last quarter. Virginia Retirement Systems ET AL lifted its stake in Lantheus by 8.3% during the third quarter. Virginia Retirement Systems ET AL now owns 55,000 shares of the medical equipment provider’s stock worth $822,000 after purchasing an additional 4,200 shares during the last quarter. Texas Permanent School Fund lifted its stake in Lantheus by 23.5% during the third quarter. Texas Permanent School Fund now owns 24,099 shares of the medical equipment provider’s stock worth $360,000 after purchasing an additional 4,580 shares during the last quarter. Raymond James & Associates lifted its stake in Lantheus by 43.6% during the second quarter. Raymond James & Associates now owns 15,561 shares of the medical equipment provider’s stock worth $226,000 after purchasing an additional 4,721 shares during the last quarter. Finally, Comerica Bank lifted its stake in Lantheus by 14.9% during the third quarter. Comerica Bank now owns 37,336 shares of the medical equipment provider’s stock worth $492,000 after purchasing an additional 4,833 shares during the last quarter. 90.73% of the stock is owned by hedge funds and other institutional investors.

Lantheus stock opened at $14.96 on Friday. Lantheus has a 52 week low of $12.59 and a 52 week high of $24.45. The company has a debt-to-equity ratio of 4.76, a current ratio of 3.50 and a quick ratio of 2.87. The stock has a market cap of $587.74 million, a P/E ratio of 14.96, a price-to-earnings-growth ratio of 3.55 and a beta of 1.36.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, October 30th. The medical equipment provider reported $0.24 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.18 by $0.06. Lantheus had a return on equity of 83.95% and a net margin of 36.75%. The business had revenue of $88.90 million during the quarter, compared to analysts’ expectations of $83.53 million. During the same period in the previous year, the business earned $0.24 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. As a group, equities research analysts predict that Lantheus will post 0.86 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Read More: Stock Symbols and CUSIP Explained

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply